Alexion buys rare diseases biotech Syntimmune for up to $1.2bn
But Alexion shares hit by EU patent ruling
Wilson’s board has unanimously accepted the offer
New drug is in patient-friendly subcutaneous form
Alexion cuts collaborations with Moderna Therapeutics, Blueprint Medicines and Arbutus Biopharma
Simon Stevens hails success in negotiating with pharma companies on price and data, and has defended NHS England’s record in promoting innovative medicines.